Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
BioDrugs
Erschienen in: BioDrugs 2/2001

01.02.2001 | Leading Article

The Potential Role of Tocopherol in Asthma and Allergies

Modification of the Leukotriene Pathway

verfasst von: Dr Stefano Centanni, Pierachille Santus, Fabiano Di Marco, Francesca Fumagalli, Simona Zarini, Angelo Sala

Erschienen in: BioDrugs | Ausgabe 2/2001

Einloggen, um Zugang zu erhalten

Abstract

Metabolism of arachidonic acid via the 5-lipoxygenase (5-LO) pathway leads to the formation of hydroperoxyeicosatetraenoic acids (HPETEs) and leukotriene (LT) A4. This unstable allylic epoxide can be further converted by secondary enzymes into LTB4 and cysteinyl LTs. LTs represent a family of potent biologically active compounds synthesised by specific cell types and by transcellular biosynthetic mechanisms. Cysteinyl LTs are involved in the pathogenesis of asthma, and recent data indicate that individuals with asthma may have enhanced basal excretion of urinary LTE4 compared with normal individuals.
Tocopherol (vitamin E) and tocopherol acetate strongly inhibit potato 5-LO in an irreversible and noncompetitive way, and, by affecting the redox state of cells possessing 5-LO, they may influence the production of biologically active LTs. It has been reported that normal plasma levels of tocopherol may enhance the lipoxygenation of arachidonic acid, whereas higher tocopherol levels exert a suppressive effect that is consistent with its role as a hydroperoxide scavenger.
Receptor-mediated activation of neutrophils in individuals with asthma results in the synthesis of LTs. This activation is inhibited by tocopherol in a concentration-dependent manner. Additional controlled studies are needed to assess the effect of tocopherol on leukotriene production in asthmatic individuals. The results of these studies may be useful in developing new therapeutic approaches in asthmatic/allergic patients.
Literatur
1.
Dennis E. Diversity of group types, regulation and function of phospholipases A2. J Biol Chem 1994; 269: 13057–60PubMed
2.
Samuelsson B, Goldyne NE, Granstrom E, et al. Prostaglandins and thromboxane. Annu Rev Biochem 1978; 47: 997–1003PubMedCrossRef
3.
4.
Kuhn H, Thiele BJ. Arachidonate 15-lipoxygenase. J Lipid Mediat Cell Signal 1995; 12: 157–70PubMedCrossRef
5.
Miller DK, Gillard JW, Vickers PJ, et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990; 343: 278–81PubMedCrossRef
6.
Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C: a slow reacting substance (SRS) from murine mastocytoma cells. Proc Natl Acad Sci USA 1979; 76: 4275–9PubMedCrossRef
7.
Drazen JM, Austen KF, Lewis RA, et al. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci USA 1980; 77: 4354–8PubMedCrossRef
8.
Hedqvist P, Dahlén SE, Gustafsson LE, et al. Biological profile of leukotrienes C4 and D4. Acta Physiol Scand 1980; 110: 331–3PubMedCrossRef
9.
Dahlén SE, Hedqvist P, Hammarstrom S, et al. Leukotrienes are potent constrictors of human bronchi. Nature 1980; 288: 484–6PubMedCrossRef
10.
Hanna CJ, Bach MK, Pare PD, et al. Slow reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle. Nature 1981; 290: 343–4PubMedCrossRef
11.
Jones TR, Davies C, Daniel EE. Pharmacological study of the contractile activity of leukotriene C4 and D4 on isolated human airway smooth muscle. Can J Physiol Pharmacol 1982; 60: 638–43PubMedCrossRef
12.
Borgeat P, Samuelsson B. Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes. Formation of a novel dihydroxy eicosanoic acid. J Biol Chem 1979; 254: 2643–6PubMed
13.
Borgeat P, Hamberg M, Samuelsson B. Transformation of arachidonic acid and homo-τ-linolenic acid by rabbit polymorphonuclear leukocytes. Monohydroxyacids from novel lipoxygenases. J Biol Chem 1977; 252: 8772
14.
Sirois P, Roy S, Borgeat P, et al. Evidence for a mediator role of thromboxane A2 in the myotropic action of leukotriene B4 (LTB4) on the guinea-pig lung. Prostaglandins Leukot Med 1982; 8: 157–70PubMedCrossRef
15.
Ford-Hutchinson AW, Brey MA, Doig MV, et al. Leukotriene B4, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980; 286: 264–5PubMedCrossRef
16.
Dahlén SE, Bjork J, Hedqvist P, et al. Leukotrienes promote plasma leakage and leukocyte adhesion in post capillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA 1981; 78: 3387–91CrossRef
17.
Hafström I, Palmblad J, Malmsten C, et al. Leukotriene B4 — a stereospecific stimulator for release of lysosomal enzymes from neutrophils. FEBS Lett 1981; 130: 146–8PubMedCrossRef
18.
Rae SA, Smith MJH. The stimulation of lysosomal enzyme secretion from human polymorphonuclear leukocytes by leukotriene B4. J Pharm Pharmacol 1981; 33: 616–8PubMedCrossRef
19.
Claesson HE, Odlander B, Jakobsson PJ, et al. Leukotriene B4 in the immune system. Int J Immunopharmacol 1982; 14: 441–9CrossRef
20.
Yamaoka KA, Dugas B, Paul-Eugene N, et al. Leukotriene B4 enhances IL-4-induced IgE production from normal human lymphocytes. Cell Immunol 1994; 156: 124–34PubMedCrossRef
21.
Davidson AE, Lee TH, Scanlon PD, et al. Bronchoconstrictor effects of LTE4 in normal and asthmatic subjects. Am Rev Respir Dis 1987; 135:333–7PubMed
22.
Israel E, Fisher AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447–51PubMedCrossRef
23.
Knani J, Campbell A, Enander I, et al. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretion of patients with chronic rhinitis. J Allergy Clin Immunol 1992; 90: 880–90PubMedCrossRef
24.
Volovitz B, Osur SL, Bernstein JM, et al. Leukotriene C4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children. J Allergy Clin Immunol 1988; 82: 414–8PubMedCrossRef
25.
Jung TTK, Juhn SK, Hwang D, et al. Prostaglandins, leukotrienes and other arachidonic acid metabolites in nasal polyps and nasal mucosa. Laryngoscope 1987; 97: 184–9PubMedCrossRef
26.
Criticos PS, Peters SP, Atkinson Jr NF, et al. Petpide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med 1984; 310: 1626–30CrossRef
27.
Shaw RJ, Fitzharris P, Cromwell O, et al. Allergen-induced release of sulphidopeptide leukotrienes (SRS-A) and LTB4 in allergic rhinitis. Allergy 1985; 40: 1–6PubMedCrossRef
28.
Miadonna A, Tedeschi A, Leggieri E, et al. Behaviour and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis. Am Rev Respir Dis 1987; 114: 522–4
29.
Liu MC, Dubé LM, Lancaster J, and the zileuton study group. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. J Allergy Clin Immunol 1996; 98: 859–71PubMedCrossRef
30.
Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991; 337: 1062–3PubMedCrossRef
31.
Cluzel M, Damon M, Chanez P, et al. Enhanced alveolar cell luminol-dependent chemiluminescence in asthma. J Allergy Clin Immunol 1987; 80: 195–201PubMedCrossRef
32.
Gorski F, Krakowiak A, Ruta U, et al. Eosinophil and neutrophil chemiluminescence in patients with atopic asthma and in healthy subjects. Allergol Immunopathol Madr 1993; 21: 71–4PubMed
33.
Vachier I, Damon M, Le Doucen C, et al. Increased oxygen species generation in blood monocytes of asthmatic patients. Am Rev Respir Dis 1992; 146: 1161–6PubMed
34.
Montuschi P, Corradi M, Ciabattoni G, et al. Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med 1999; 160: 216–20PubMed
35.
Kelly FJ, Mudway I, Blomberg A, et al. Altered lung antioxidant status in patients with mild asthma. Lancet 1999; 354: 482–3PubMedCrossRef
36.
Malmgren R, Unge G, Zetterstrom O, et al. Lowered glutathione peroxidase activity in asthmatic patients with food and aspirin intolerance. Allergy 1986; 41: 43–5PubMedCrossRef
37.
Pearson DJ, Suarez-Mendez VJ, Day JP, et al. Selenium status in relation to glutathione peroxidase activity in aspirin-sensitive asthma. Clin Exp Allergy 1991; 21: 203–8PubMedCrossRef
38.
Stone J, Hinks LJ, Beasley R, et al. Reduced selenium status of patients with asthma. Clin Sci 1989; 77: 495–500PubMed
39.
Flatt A, Pearce N, Thomson CD, et al. Reduced selenium in asthmatic subjects in New Zeland. Thorax 1990; 45: 95–9PubMedCrossRef
40.
Barnes PJ. New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. J Allergy Clin Immunol 1989; 83: 1013–26PubMedCrossRef
41.
Beasley R, Thomson C, Pearce N. Selenium, glutathione peroxidase and asthma. Clin Exp Allergy 1991; 21: 157–9PubMedCrossRef
42.
Rouzer CA, Matsumoto T, Samuelsson B. Single protein from human leukocytes possesses 5-lipoxygenase and leukotriene A4 synthase activities. Proc Natl Acad Sci USA 1986; 83: 857–61PubMedCrossRef
43.
Tappel AL. Vitamin E and free radical peroxidation of lipids. Ann N Y Acad Sci 1972; 203: 12–28PubMedCrossRef
44.
Hoekstra WG. Biochemical function of selenium and its relation to vitamin E. Fed Proc 1975; 34: 2083–9PubMed
45.
Combs Jr GP, Noguchi T, Scott ML. Mechanism of action of selenium and vitamin E in protection of biological membranes. Fed Proc 1975; 34: 2090–95PubMed
46.
Goetzl EJ. Vitamin E modulates the lipoxygenation of arachidonic acid in leukocytes. Nature 1980; 288: 183–5PubMedCrossRef
47.
Harris RE, Boxer LA, Baehner RL. Consequences of vitamin E deficiency on the phagocytic and oxidative functions of the rat polymorphonuclear leukocyte. Blood 1980; 55: 338–43PubMed
48.
Steiner M, Anastasi J. Vitamin E: an inhibition of the platelet release reaction. J Clin Invest 1976; 57: 732–7PubMedCrossRef
49.
Hatam LJ, Traber MG, Kaydet HJ. The measurement of nanograms of tocopherol from needle aspiration biopsies of adipose tissue: normal and abetalipoproteinemic subjects. J Lipid Res 1979; 20: 639–45PubMed
50.
Villa S, Lorico A, Morazzoni G, et al. Vitamin E and vitamin C inhibit arachidonate-induced aggregation of human peripheral blood leukocytes in vitro. Agents Actions 1986; 19: 127–31PubMedCrossRef
51.
Reddanna P, Rao MK, Reddy CC. Inhibition of 5-lipoxygenase by vitamin E. FEBS Lett 1985; 193: 39–43PubMedCrossRef
52.
Kuo CF, Cheng S, Burgess JR. Deficiency of vitamin E and selenium enhances calcium-independent phospholipase A2 activity in rat lung and liver. J Nutr 1995; 125: 1419–29PubMed
53.
Centanni S, Santus P, Carlucci P, et al. Tocopherol inhibits leukotriene production by human neutrophils in asthmatic subjects. Eur Respir J 1999; 14Suppl. 30: 527S–8S
54.
Luostarinen R, Siegbahn A, Saldeen T. Effects of dietary supplementation with vitamin E on human neutrophil chemotaxis and generation of LTB4. Ups J Med Sci 1991; 96: 103–11PubMedCrossRef
55.
Hansson G, Lindgren JÅ, Dahlén S-E, et al. Identification and biological activity of novel ω-oxidized metabolites of leukotriene B4 from human leukocytes. FEBS Lett 1981; 130: 107–12PubMedCrossRef
56.
Kohlschütter A, Mayatepek E, Finckh B, et al. T. Effect of plasma α-tocopherol on leukotriene E4 excretion in genetic vitamin E deficiency. J Inherit Metab Dis 1997; 20: 581–6PubMedCrossRef
57.
Suzuki N, Hishinuma T, Abe F, et al. Difference in urinary LTE4 and 11-dehydro-TXBZ excretion in asthmatic patients. Prostaglandins 2000; 62(4): 395–403CrossRef
Metadaten
Titel
The Potential Role of Tocopherol in Asthma and Allergies
Modification of the Leukotriene Pathway
verfasst von
Dr Stefano Centanni
Pierachille Santus
Fabiano Di Marco
Francesca Fumagalli
Simona Zarini
Angelo Sala
Publikationsdatum
01.02.2001
Verlag
Springer International Publishing
Erschienen in
BioDrugs / Ausgabe 2/2001
Print ISSN: 1173-8804
Elektronische ISSN: 1179-190X
DOI
https://doi.org/10.2165/00063030-200115020-00002